Pharmafile Logo

Poisson Rouge

Poisson Rouge is a London based company that specialises in producing unique and high impact teambuilding activities, people development programmes and event management services. For nearly 20 years we have been combining our passion and creativity to create some of the most unusual, fun, and exciting team events and some of the most innovative ways to develop people available anywhere on Earth. However, instead of wanging on about how great we think we are we thought we’d just let our unique ideas, our long track record of success and our clients do the talking!

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Amiculum

AMICULUM works with the global healthcare industry to bring science to life across the product lifecycle from early opportunity assessment through to launch and beyond. By listening to the changing…

View Profile

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.

View Profile

Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education to life science companies from around the globe since 2008.

View Profile

M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors with over 6 million members across M3-owned networks and an…

View Profile

OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health outcomes and patient wellbeing.

View Profile

Company Details

96 west yard, Camden Lock Place, London, N6 6BL, United Kingdom
+44 (0)20 7267 3646

 Latest Content from PMHub 

Alzheimer’s disease: reviewing the immediate treatment horizon

Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.

A stumble, but not a fall – what’s next for Opdivo?

Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

Meet Anthill at conferences in London

October, the month of multichannel pharma marketing in London. Meet us at DigiPharm and Multichannel Excellence Summit

Immuno-oncology; bringing patients closer to treatment

What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?

Therapy Watch market snapshots

Therapy Watch is a ‘real-time’ syndicated market tracking tool that provides marketing teams, brand managers and market researchers with strategic and tactical market information. Run entirely online to ensure speed,...

Case Study: Private market opportunity for a travel vaccine

Our client needed exploratory research to determine the global opportunity for a new travel vaccine in the private market. It was crucial to determine:Which markets had the highest potential to...

Infographic: Conference Live

Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients...

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...